Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome
| Autor: | Chao Chang, Shuan-Li Xin, Zhi-Jiang Xie, Xiu-feng Zhao, Tao Li, Chuan Chen, Feng-Hui Jiao, Hai-Jing Zhou |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Ticagrelor Epidemiology Cardiovascular Procedures Myocardial Infarction Disease Cardiovascular Medicine 030204 cardiovascular system & hematology Vascular Medicine Medical Conditions 0302 clinical medicine Medicine and Health Sciences Medicine Drug Interactions 030212 general & internal medicine Myocardial infarction Multidisciplinary Pharmaceutics Cardiogenic shock Hematology Middle Aged Stroke Neurology Cardiovascular Diseases Cardiology Female Research Article medicine.drug Acute coronary syndrome medicine.medical_specialty Coronary Stenting Combination therapy Science Cerebrovascular Diseases Hemorrhage Surgical and Invasive Medical Procedures Platelet Glycoprotein GPIIb-IIIa Complex 03 medical and health sciences Signs and Symptoms Drug Therapy Internal medicine Humans cardiovascular diseases Acute Coronary Syndrome Blood Coagulation Ischemic Stroke Coagulation Disorders business.industry Thrombosis Cardiovascular Disease Risk medicine.disease Medical Risk Factors Multivariate Analysis Stent Implantation Clinical Medicine business Glycoprotein IIb/IIIa Receptor Antagonist Therapy Mace |
| Zdroj: | PLoS ONE PLoS ONE, Vol 16, Iss 2, p e0246166 (2021) |
| ISSN: | 1932-6203 |
| DOI: | 10.1371/journal.pone.0246166 |
| Popis: | This study was to compare the efficacy and safety of combined glycoprotein IIb/IIIa inhibitor (GPI) and ticagrelor versus ticagrelor in patients with acute coronary syndrome (ACS). An observational study was conducted using the Improving Care for Cardiovascular Disease in China-ACS project. Totally, 13,264 patients with ACS and received combination therapy or ticagrelor therapy were analyzed. The primary outcome was the composite of major cardiovascular events (MACE: all-cause mortality, myocardial infarction [MI], stent thrombosis, cardiogenic shock, and ischemic stroke), and secondary outcomes included all-cause mortality, MI, stent thrombosis, cardiogenic shock, and ischemic stroke. The multivariable adjusted analysis indicated that combination therapy was associated with an increased risk of major cardiovascular events (MACE) (P = 0.001), any bleeding (PP = 0.005). Moreover, the multivariable adjusted for propensity score-matched (PSM) analysis suggested that combination therapy produced additional risk of MACE (P = 0.014), any bleeding (PP = 0.005). Moreover, PSM analysis suggested that combination therapy was associated with greater risk of stent thrombosis (P = 0.012) and intracranial bleeding (P = 0.020). Combined GPI and ticagrelor therapies did not have any beneficial effects on MACE, stent thrombosis, intracranial bleeding, any bleeding, or major bleeding. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|